|
|
|
Wednesday, 08 October 2008 |
Oncolytics Biotech production of REOLYSIN (R) transitions to commercial scale
|
|
Wednesday, 08 October 2008 |
Boston Scientific's enrollment for third-generation DES clinical trial completed
|
|
Tuesday, 07 October 2008 |
Sanofi Pasteur obtains license for 3M vaccine adjuvants
|
|
Monday, 06 October 2008 |
Orexigen presents data on naltrexone sustained release in Contrave(R)
|
|
Friday, 03 October 2008 |
Crucell awarded NIAID/NIH contract to develop vaccine against Ebola and Marburg
|
|
Thursday, 02 October 2008 |
Emisphere publishes clinical study on the effects of oral administration of GLP-1 and PYY3-36
|
|
Wednesday, 01 October 2008 |
US Government agrees upon new anthrax vaccine contract with Emergent Biosolutions
|
|
Tuesday, 30 September 2008 |
SurModics announces acquisition of CodeLink(TM) Activated Slide microarray business
|
|
Tuesday, 30 September 2008 |
ULURU files a 510k submission with FDA for Altrazeal(TM) Silver
|
|
Monday, 29 September 2008 |
Columbia Laboratories announces poor Phase II clinical trial results of vaginal lidocaine
|
|
Friday, 26 September 2008 |
DSMB OKs Iluvien(TM) Phase III clinical trial continuation for pSivida DME treatment
|
|
Friday, 26 September 2008 |
New financing round nets Novagali Pharma 15 Million euros
|
|
Friday, 26 September 2008 |
Eli Lilly's LAI schizophrenia formulation recommended for European approval
|
|
Friday, 26 September 2008 |
Indevus and FDA in agreement on measures to approve NEBIDO(R) for late 2009
|
|
Friday, 26 September 2008 |
IDM Pharma confident of EC final decision regarding mifamurtide for osteosarcoma treatment
|
|
Friday, 26 September 2008 |
King Pharmaceuticals offer unanimously rejected by Alpharma board
|
|
Thursday, 25 September 2008 |
CTI regains partial NASDAQ Compliance; further pending
|
|
Wednesday, 24 September 2008 |
NeutrogesX announces on schedule response to EMEA's day 120 questions
|
|
Tuesday, 23 September 2008 |
Tris Pharma receives FDA OK after facilities' expansion
|
|
Tuesday, 23 September 2008 |
Abstral cancer pain drug approved for UK marketing
|
|
Monday, 22 September 2008 |
Phase III for Emisphere's oral calcitonin to start
|
|
Monday, 22 September 2008 |
Alpharma agreement with DURECT on ELADUR(TM)
|
|
Friday, 19 September 2008 |
Novovax phase II testing of VLP seasonal influenza vaccine to bring benefits
|
|
Friday, 19 September 2008 |
FDA requests PDUFA extension to complete Zolpimist review
|
|
Thursday, 18 September 2008 |
Neose Technologies, to sell its assets for $43 million
|
|
Thursday, 18 September 2008 |
License agreement between Flamel Technologies and Wyeth Pharmaceuticals continues
|
|
Thursday, 18 September 2008 |
A proposed merger between BTG and Protherics is seen as favorable
|
|
Wednesday, 17 September 2008 |
Depomed to start Phase III clinical trial for Gabapentin
|
|
Wednesday, 17 September 2008 |
Merck discontinues collaboration with SurModics
|
|
Tuesday, 16 September 2008 |
Javelin completes patient enrollment for second of two phase III studies of Dyloject(TM)
|
|
Tuesday, 16 September 2008 |
Pfizer transitions Exubera patients to Mannkind's inhaled insulin
|
|
Tuesday, 16 September 2008 |
Oramed announces launch of pre-clinical trials for oral diabetes management drug
|
|
Tuesday, 16 September 2008 |
Generex starts Oral-lyn phase III trial
|
|
Monday, 15 September 2008 |
QLT announces CDN$65.5 million real estate transaction as well as complete redemption of notes
|
|
Monday, 15 September 2008 |
EpiCept amends DURECT Bupivacaine patch licensing agreement
|
|
Monday, 15 September 2008 |
Cephalon implementing FDA requested FENTORA(R) enhancements
|
|
Saturday, 13 September 2008 |
RAD001 combined with Sandostatin LAR(R) Depot controls growth of pancreatic neuroendocrine tumors
|
|
Wednesday, 10 September 2008 |
Alpharma reports positive Embeda(TM) pain drug data
|
| |
|
Results 51 - 88 of 88 |
